Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal–systemic concentration difference method

References

• Baarnhielm C, Dahlback H, Skanberg I. (1986). In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol (Copenh) 59:113–22
   PubMedGoogle Scholar
• Bai S, Stepkowski SM, Kahan BD, et al. (2004). Metabolic interaction between cyclosporine and sirolimus. Transplantation 77:1507–12
   PubMed Web of Science ®Google Scholar
• Benet LZ, Izumi T, Zhang Y, et al. (1999). Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 62:25–31
   PubMed Web of Science ®Google Scholar
• Cao X, Gibbs ST, Fang L, et al. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675–86
   PubMed Web of Science ®Google Scholar
• Chen M, Xu D, Hu XL, et al. (2008). Effects of liver fibrosis on verapamil pharmacokinetics in rats. Clin Exp Pharmacol Physiol 35:287–94
   PubMed Web of Science ®Google Scholar
• Chiou WL, Barve A. (1998). Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15:1792–5
   PubMed Web of Science ®Google Scholar
• Chovan JP, Ring SC, Yu E, et al. (2007). Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica 37:459–73
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Fagerholm U, Johansson M, Lennernas H. (1996). Comparison between permeability coefficients in rat and human jejunum. Pharm Res 13:1336–42
   PubMed Web of Science ®Google Scholar
• Fujieda Y, Yamaoka K, Ito T, et al. (1996). Local absorption kinetics of levofloxacin from intestinal tract into portal vein in conscious rat using portal-venous concentration difference. Pharm Res 13:1201–4
   PubMed Web of Science ®Google Scholar
• Furukawa T, Nakamori F, Tetsuka K, et al. (2012). Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. Drug Metab Pharmacokinet 27:171–80
   PubMed Web of Science ®Google Scholar
• Furukawa T, Naritomi Y, Tetsuka K, et al. (2013). Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys. Xenobiotica. [Epub ahead of print]. doi: 10.3109/00498254.2013.828362
   PubMed Web of Science ®Google Scholar
• Gertz M, Harrison A, Houston JB, et al. (2010). Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147–58
   PubMed Web of Science ®Google Scholar
• Gill KL, Houston JB, Galetin A. (2012). Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos 40:825–35
   PubMed Web of Science ®Google Scholar
• Grundy JS, Eliot LA, Foster RT. (1997). Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharm Drug Dispos 18:509–22
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Martin MV, Beaune PH, et al. (1986). Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051–60
   PubMed Web of Science ®Google Scholar
• Higuchi S, Shiobara Y. (1980). Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica 10:447--54
   Google Scholar
• Hirunpanich V, Katagi J, Sethabouppha B, et al. (2006). Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. Drug Metab Dispos 34:305–10
   PubMed Web of Science ®Google Scholar
• Hoffman DJ, Seifert T, Borre A, et al. (1995). Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm Res 12:889–94
   PubMed Web of Science ®Google Scholar
• Kadono K, Akabane T, Tabata K, et al. (2010). Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab Dispos 38:1230–7
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Fasco MJ. (1991). Small intestinal cytochromes P450. Crit Rev Toxicol 21:407–22
   PubMed Web of Science ®Google Scholar
• Kato M, Chiba K, Hisaka A, et al. (2003). The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365–72
   PubMedGoogle Scholar
• Komura H, Iwaki M. (2011). In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Drug Metab Rev 43:476–98
   PubMed Web of Science ®Google Scholar
• Komura H, Yasuda M, Yoshida NH, et al. (2002). Species difference in nisoldipine oxidation activity in the small intestine. Drug Metab Pharmacokinet 17:427–36
   PubMedGoogle Scholar
• Lebrec D, Blanchet L. (1985). Effect of two models of portal hypertension on splanchnic organ blood flow in the rat. Clin Sci (Lond) 68:23–8
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim EJ, Kwon JW, et al. (2006). Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats. Biopharm Drug Dispos 27:125–31
   PubMed Web of Science ®Google Scholar
• Mandema JW, Tukker E, Danhof M. (1991). Pharmacokinetic–pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol 102:663–8
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Konno Y, Satsukawa M, et al. (2012). Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats. Drug Metab Dispos 40:2231–8
   PubMed Web of Science ®Google Scholar
• Mitschke D, Reichel A, Fricker G, et al. (2008). Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab Dispos 36:1039–45
   PubMed Web of Science ®Google Scholar
• Mizuma T. (2009). Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378:140–1
   PubMed Web of Science ®Google Scholar
• Nakamori F, Naritomi Y, Hosoya K, et al. (2012). Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. Drug Metab Dispos 40:1771–7
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kimura S, et al. (2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316–24
   PubMed Web of Science ®Google Scholar
• Nishimuta H, Nakagawa T, Nomura N, et al. (2013). Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs. Xenobiotica 43:944–55
   Web of Science ®Google Scholar
• Pai HV, Upadhya SC, Chinta SJ, et al. (2002). Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite. Pharmacogenom J 2:243–58
   PubMedGoogle Scholar
• Rioux N, Bellavance E, Bourg S, et al. (2013). Assessment of CYP3A-mediated drug–drug interaction potential for victim drugs using an in vivo rat model. Biopharm Drug Dispos 34:396–401
   PubMed Web of Science ®Google Scholar
• Robinson MA, Mehvar R. (1996). Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding. Biopharm Drug Dispos 17:577–87
   PubMed Web of Science ®Google Scholar
• Rowland A, Elliot DJ, Knights KM, et al. (2008a). The “albumin effect” and in vitro–in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 36:870–7
   PubMed Web of Science ®Google Scholar
• Rowland A, Gaganis P, Elliot DJ, et al. (2007). Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro–in vivo extrapolation. J Pharmacol Exp Ther 321:137–47
   PubMed Web of Science ®Google Scholar
• Rowland A, Knights KM, Mackenzie PI, et al. (2008b). The “albumin effect” and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056–62
   PubMed Web of Science ®Google Scholar
• Shiraga T, Matsuda H, Nagase K, et al. (1994). Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 47:727–35
   PubMed Web of Science ®Google Scholar
• Stopher DA, Beresford AP, Macrae PV, et al. (1988). The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 12:S55–9
   PubMed Web of Science ®Google Scholar
• Surya Sandeep M, Sridhar V, Puneeth Y, et al. (2013). Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. Drug Dev Ind Pharm. [Epub ahead of print]. doi: 10.3109/03639045.2013.819885
   PubMed Web of Science ®Google Scholar
• Tabata K, Yamaoka K, Fukuyama T, et al. (1995). Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm Res 12:880–3
   PubMed Web of Science ®Google Scholar
• Tang C, Lin Y, Rodrigues AD, et al. (2002). Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab Dispos 30:648–54
   PubMed Web of Science ®Google Scholar
• Wang Y, Roy A, Sun L, et al. (1999). A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos 27:855–9
   PubMed Web of Science ®Google Scholar
• Wattanachai N, Polasek TM, Heath TM, et al. (2011). In vitro--in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol 67:815–24
   PubMed Web of Science ®Google Scholar
• Wattanachai N, Tassaneeyakul W, Rowland A, et al. (2012). Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro–in vivo extrapolation of drug clearance. Drug Metab Dispos 40:982–9
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Tanigawara Y, Nakagawa T, et al. (1981). A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879–85
   PubMedGoogle Scholar
• Yang J, Jamei M, Yeo KR, et al. (2007). Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676–84
   PubMed Web of Science ®Google Scholar
• Zhao YH, Abraham MH, Le J, et al. (2003). Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem 38:233–43
   PubMed Web of Science ®Google Scholar
• Zhou YN, Zhang BK, Li J, et al. (2013). Effect of amlodipine on the pharmacokinetics of tacrolimus in rats. Xenobiotica 43:699–704
   PubMed Web of Science ®Google Scholar